bioMérieux : CA T3 2024 : dans le haut des attentes – Eléments de guidance confortés
>T3 2024: +7,8% avec +11% lfl. (vs +9,9% au S1) - Le CA T3 se monte à 969 M€, +7,8% (soit +11% lfl.). A 9M, les ventes atteignent 2871M€ (+7,6% et +10,3% lfl.), impacté par un effet devises de -76 M€ soit -26 M€ au T3 (vs -44 M€ à fin juin).bioMérieux maintient sa guidance, à savoir une croissance comprise entre 8% et 10% à tcc. (CSS : 3941 M€ +9,2%e – ODDO BHF : +8,5%e), avec un impact FX attendu à -60 M€ (vs 70 M€ précédemment), pour un ROCc. en hausse de 12 % ...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.